Cerus Q1 revenue rises, beats estimates
Overview
Blood safety technology firm's Q1 revenue rose 23% yr/yr, beating analyst expectations
Q1 adjusted EBITDA beat consensus, driven by strong INTERCEPT Fibrinogen Complex demand
Company raised full-year 2026 product revenue guidance to $227 mln-$231 mln, up 10%-12% yr/yr
Outlook
Cerus raises 2026 product revenue guidance to $227 mln-$231 mln, up 10%-12% from 2025
Company expects 2026 IFC revenue between $22 mln and $24 mln
Cerus cites anticipated regulatory and clinical milestones as catalysts for 2026
Result Drivers
IFC DEMAND - Co said Q1 growth was primarily driven by increased demand for INTERCEPT Fibrinogen Complex, with volumes up about 120% yr/yr and higher U.S. sales
PLATELET FRANCHISE - Global platelet franchise contributed to product revenue growth, per company
GOVERNMENT CONTRACTS - Higher government contract revenue driven by BARDA and Department of Defense projects
Company press release: ID:nBw3cdwY3a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Beat | $59.90 mln | $53.17 mln (3 Analysts) |
Q1 EPS |
| -$0.01 |
|
Q1 Net Income |
| -$1.60 mln |
|
Q1 Adjusted EBITDA | Beat | $4 mln | $33,330 (3 Analysts) |
Q1 Gross Margin |
| 52.00% |
|
Q1 Gross Profit |
| $27.90 mln |
|
Q1 Operating Expenses |
| $34.48 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Cerus Corp is $5.00, about 160.4% above its April 29 closing price of $1.92
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
Recommended Articles
Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.